ARTICLE | Product Development
Two upcoming readouts could shape the market for κ-opioid antidepressants
Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia
November 6, 2024 8:30 PM UTC
Upcoming readouts from late-stage studies of κ-opioid receptor antagonists from Neumora and J&J could shape a nascent market for antidepressants that address anhedonia, the inability to feel pleasure.
The first results from Phase III trials of KOR antagonists navacaprant from Neumora Therapeutics Inc. (NASDAQ:NMRA) and aticaprant from Johnson & Johnson (NYSE:JNJ), both due by year-end, will include efficacy data on both a primary endpoint measuring depression scores and secondary endpoints measuring anhedonia, among patients with major depressive disorder (MDD)...